Novavax (NVAX) Is Up 25.9% After Pfizer Matrix-M Deal And Q1 Beat On Expectations
In early May 2026, Novavax reported first-quarter revenue of US$139.51 million versus US$666.66 million a year earlier, swinging…
How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
In early May 2026, Pfizer reported first-quarter revenue of US$14.45 billion and net income of US$2.69 billion, with earnings per…
Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with…
Johnson & Johnson Vs. Pfizer
As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify…
A Healthcare Stock With a 6%-Plus Yield: Is the Dividend Safe?
Although high dividend yields are attractive to income seekers, they can sometimes signal that the dividend is unsustainable…
The Best Healthcare Stocks to Buy With $50 Right Now
It’s not hard to find healthcare stocks, including small-cap biotech companies, trading below $50 per share. However, many…
3 Healthcare Stocks Paying the Highest Dividends of 2026
Could your portfolio use some more exposure to the healthcare sector as well as more income? If so,…
2 Top AI Healthcare Stocks to Buy and Hold
Many of the top companies successfully cashing in on artificial intelligence (AI) are in the technology sector. However,…
List of medications seeing major price changes in 2026
A number of major drugmakers have reportedly raised the prices of hundreds of brand-name drugs, including some of…
Pfizer’s Braftovi Combo Wins FDA Approval
The U.S. Food and Drug Administration has granted full approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy…
This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income
Pfizer (NYSE: PFE) is one of the world’s largest and most respected pharmaceutical companies. That is an important…
Is Pfizer Stock an Underrated Healthcare Investment Play?
Pharmaceutical giant Pfizer (NYSE: PFE) recently had to drop its internally developed GLP-1 weight loss drug candidate. The…